BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes.

Area of Science:

• Oncology
• Pulmonology
• Toxicology

Background:

• Carmustine (BCNU) is a chemotherapy agent used for treating brain tumors like astrocytoma.
• Long-term BCNU therapy is associated with potential pulmonary toxicity.
• Understanding the spectrum of BCNU-induced lung injury is crucial for patient management.

Observation:

• Two patients with astrocytoma grade II treated with long-term BCNU therapy developed distinct pulmonary complications.
• One patient experienced rapidly fatal lung disease with atypical pneumocyte proliferation and inflammation.
• The second patient exhibited slowly progressive dyspnea due to severe diffuse alveolar septal fibrosis.

Findings:

• Pulmonary disease presentation and histopathological findings varied significantly between the two patients.
• The observed differences suggest individual variability in response to BCNU-induced lung toxicity.
• Specific tissue alterations included atypical pneumocyte proliferation, interstitial inflammation, fibrosis, and hyaline membranes.

Implications:

• Highlights the need for vigilant monitoring of pulmonary function in patients undergoing long-term BCNU treatment.
• Suggests that patient-specific factors may influence the development and severity of BCNU-related lung damage.
• Emphasizes the importance of recognizing diverse clinical and pathological manifestations of chemotherapy-induced pulmonary toxicity.